Home
Search
Search Results
Previously Searched
3083 results found
Expand All
Apply All
3083 results found

Biotechnology is a National Security Asset
I am BIO Podcast  •  September 24, 2024
Since Watson and Crick discovered DNA's double helix structure in 1953, the US has been a leader in biotechnology innovation. American excellence in this field has greatly benefited people around the world. In this episode, we talk about why this leadership position may be threatened and why that matters to our national security.
Read More
podcast

BIO Clinical Trial Diversity

PPRV reauthorization, IRA, and BIO's Governor of the Year
Good Day BIO Newsletter  •  September 23, 2024
A busy week in Washington brought progress on Pediatric Disease Priority Review Voucher (PPRV) reauthorization and conversations on price controls. Plus, BIO names Virginia Gov. Glenn Youngkin Governor of the Year. (790 words, 3 minutes, 57 seconds)
Read More

Virginia Governor Glenn Youngkin named BIO’s Governor of the Year
Press Release  •  September 17, 2024
WASHINGTON, DC (September 17, 2024) – Today, the Biotechnology Innovation Organization (BIO) awarded Virginia Governor Glenn Youngkin with its 2024 Governor of the Year Award. BIO’s annual award honors governors for their leadership and commitment to strengthening biotechnology in their state. For over a decade, the award has recognized governors from across the country and both sides of the aisle.“Investing in biotechnology is investing in Virginia’s future,” said Governor Glenn Youngkin. “As the Commonwealth’s cutting-edge research triangle and network continues to expand, my administration is determined to remain at the forefront of fostering innovation. I am incredibly humbled to receive this award, and I look forward to further solidifying Virginia’s role as a leader in the life sciences industry.”“It is my honor to recognize Governor Youngkin with BIO’s 2024 Governor of the Year award for his leadership and support of the life sciences in Virginia,” said BIO President and CEO John F. Crowley. “From advancing innovative economic development initiatives for the bioscience ecosystem to investing in cutting-edge life science facilities across the state, Governor Youngkin has worked tirelessly on public policy solutions to help expand opportunities for researchers, entrepreneurs, and patients in Virginia.” "Virginia's $8 billion biotechnology industry is thriving because of the steadfast support of our governmental leaders and regional partnerships," said John Newby, CEO of the Virginia Biotechnology Association. "We thank Governor Youngkin and his administration for making transformational investments in our ecosystem, and for promoting pro-innovation policies that bring life-improving technologies to patients."###About BIOBIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO…
Read More

Privacy Policy
Thank you for visiting a member of the Biotechnology Innovation Organization (BIO) family of websites.  BIO and possibly affiliated organizations (“BIO” “we,” “our,” “us”) maintain these sites (each, strictly for reference in this privacy policy, a “BIO Site” and collectively “BIO Sites”). This privacy policy (the "Privacy Policy") applies to BIO Sites, mobile applications, and other online services that link to this Privacy Policy (the “Services”). By using the Services, you agree to the terms of this Privacy Policy.  In addition, by using the Services, you agree to the terms of the BIO TERMS OF USE, which govern your use of the Services.   Please note that the Privacy Policy does not apply to other websites of other companies, organizations or our members to which we may link, third party sites that link to us, or to our off-line activities.IF YOU DO NOT AGREE WITH ANY TERMS OR PRACTICES DESCRIBED IN THIS PRIVACY POLICY, OR BIO’S TERMS OF USE, THEN PLEASE DO NOT USE THE SERVICES.Information CollectionGenerally, you are not required to provide information about yourself when you visit the Services.  You can browse most of our BIO Sites and view our content anonymously (except regarding some information like Google analytics or “informatics”).  The type and amount of information BIO collects about you varies according to how you use the Services, BIO Sites or other BIO operations and events.  However, we may ask you for (or collect from you) some or all of the following types of information when you access various content or features, submit information to us, or directly contact us with questions or feedback:Contact information, such as name, e-mail address, phone number and postal address;Demographic information, such as gender, age, income, and residency status;Geolocation information and zip code information;Communication preferences and information about your interests;Search queries;Correspondence and other information that…
Read More

Poll shows strong bipartisan support for American biomanufacturing
Good Day BIO Newsletter  •  September 16, 2024
We’re packing a lot into one little newsletter: a new poll that shows strong bipartisan support for boosting American biomanufacturing, a House antitrust hearing on PBMs, and a lot more news you need to know to start your week. (762 words, 3 minutes, 48 seconds)
Read More

BIO files Amicus Brief in Colorado PDAB Case
Human Health  •  Amicus Brief  •  September 13, 2024
The Biotechnology Innovation Organization (“BIO”) respectfully moves the Court for leave to file an amicus brief in support of Plaintiffs’ response in opposition to the Defendants’ cross-motion for summary judgment. Copies of the proposed brief and proposed order are attached. Counsel for BIO has conferred with counsel for all parties: while counsel for Plaintiffs do not oppose this motion for leave to file an amicus brief, counsel for Defendants represented that Defendants oppose the motion.
Read More

CSBA urges passage of PPRV program – plus, I am BIO Podcast new season
Good Day BIO Newsletter  •  September 10, 2024
We’re back on a Tuesday, with news about the Rare Pediatric Disease Priority Review Voucher program and the BIOSECURE Act—plus, the season opener of the I am BIO Podcast. (725 words, 3 minutes, 37 seconds)
Read More

CSBA Letter to Congressional Leadership on Reauthorization of the Rare Pediatric Disease Priority Review Voucher Program
Rare Diseases, Council for State Biotechnology Associations (CSBA)  •  Letters, Testimony & Comments  •  September 10, 2024

A Doctor Fights to Save His Own Life: The David Fajgenbaum Story.
I am BIO Podcast  •  September 10, 2024
David Fajgenbaum was in his third year of medical school when he was diagnosed with a rare and life-threatening disease that began shutting down his organs, bringing him perilously close to death. Although he survived the initial episode, he faced four additional relapses, each pushing him to the brink of death. In this episode, we speak with David about his relentless journey to discover the treatment that ultimately put his disease into remission. We also explore how his personal battle inspired the creation of a groundbreaking approach to help others suffering from rare diseases.
Read More
podcast